AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: HRMY
Report Date: 2026-04-22
Full Report: https://amaly.io/stock/HRMY

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: HRMY operates in the biopharmaceutical sector focusing on rare neurological diseases. The company's financial ratios demonstrate strong compliance in debt (9.06%) and liquidity (25.87%) metrics across all standards, with non-permissible income at 0%. However, the interest income ratio, while currently low at 0.14%, has historical highs leading to flagged concerns. Overall, due to exclusion from major Shariah indices, the stock is classified as non-compliant, though suitable for review with purification. The compliance quality is moderate, reflecting solid recent performance but index and historical issues.

Primary Compliance Concerns:
- Historical interest income ratio exceeding 5% in prior years
- Exclusion from all major Shariah indices due to size and historical metrics
- Limited transparency on business activities and subsidiaries

Purification Requirement: 0.14%
Index Inclusion: Excluded from S&P Dow Jones Shariah Indices, MSCI Islamic Indices, FTSE Shariah Indices, and Dow Jones Islamic Market (DJIM).

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 9.1%
Liquidity Ratio: 25.9%
Interest Income Ratio: 0.0%
Purification Required: 0.14%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-11-30

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-22T00:00:00Z

---
Full interactive report: https://amaly.io/stock/HRMY
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.